- 2 Amplification (TMA) towards conventional qPCR chemistry on whole blood samples.
- 3 Running title: CMV diagnosis: clinical performance of TMA chemistry.
- 4 Paolo Bottino^{a#}, Lisa Pastrone^a, Elisa Zanotto^a, Francesca Sidoti^a, Cristina Costa^a, Rossana Cavallo^a
- ⁵ ^aS.C. Microbiology and Virology U., A.O.U. "Città della Salute e della Scienza di Torino" Turin (Italy)
- 7 Corresponding author:
- 8 # paolo.bottino@unito.it
- 10 Abstract word count: 249

- ___

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract. Human Cytomegalovirus (HCMV) infection represents a life-threating pathogen for 30 31 immunocompromised patients. Molecular quantitative testing on whole blood or plasma represents the gold standard for diagnosis of invasive HCMV infection and for monitoring antiviral treatment in individuals at 32 risk of CMV disease. For these reasons, accurate standardization towards the 1st WHO International standard 33 between different centres and diagnostic kits represent an effort for a better clinical management of CMV-34 positive patients. Herein, we evaluate for the first time the performance of a new TMA (Transcription 35 Mediated Amplification) kit towards qPCR chemistry, used as routine method, on whole blood samples. 755 36 clinical whole blood specimens were collected and simultaneously tested with TMA and qPCR assays. Data 37 showed 99.27% agreement for positive quantified samples and 89.39% agreement for those not detected 38 between two tested methods. Evaluation of viraemia in positive samples highlighted a good correlation for 39 TMA and qPCR chemistries in terms of International Units (ΔLog_{10} IU/ml: -0.29 ± 0.40). TMA assay showed 40 a significant correlation with qPCR also in monitored patients until three months, thus allowing accurate 41 evaluation of viraemia in transplanted patients. Moreover, preliminary data about analytical sensitivity of 42 TMA chemistry onto DBS samples showed 86.54% correlation with whole blood specimens. 43

Thus, TMA chemistry showed a good agreement with qPCR assay, used as current diagnostic routine, and offers important advantages: FDA and IVD approval on plasma and whole blood, automated workflow with minimal hands-on time, random access loading, thus enabling a rapid and reliable diagnostics in HCMVinfected patients.

- 48
- 49
- 50 Keywords: CMV; Diagnosis; Transcription Mediated Amplification; Whole blood.
- 51 52

53

54

55

56

57

Introduction. Human Cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is the 58 prototype member of the Betaherpesvirinae and the largest member of the virus family Herpesviridae (1). It 59 is a ubiquitous virus that infects almost all humans at some time in their lives. The virus was first isolated by 60 three different groups of researchers: Rowe and colleagues, Weller and colleagues, and Smith simultaneously 61 in 1956 (2). The genome is a linear, double-stranded DNA molecule with a 236 kbp size and consisting of two 62 unique regions, each flanked by inverted repeats (3). Despite enclosing a much larger genome, the size of the 63 HCMV capsid is similar to that of other herpesviruses, structured as an icosahedrally ordered nucleocapsid 64 with triangulation number (T) = 16, composed of 12 pentons, 150 hexons, and 320 triplexes (4, 5). Externally 65 to the capsid, it is located the tegument, generally thought to be unstructured and amorphous in nature. 66 However, some structuring is seen with the binding of tegument proteins to the protein capsid. The tegument 67 proteins comprise more than half of the total proteins found within infectious virions (6, 7). Finally, a lipidic 68 bilayer envelope membrane, containing several virus-specific glycoproteins, in turn covers tegument and 69 HCMV nucleocapsid. This envelope is similar in structure and composition to host cell membranes (8, 9). 70

HCMV is a global herpesvirus highly prevalent worldwide with a prevalence of about 100% in both Africa
and Asia, and 45.6-95.7% in Europe and North America (10). The heterogeneous CMV seroprevalence appear
to be related with race, ethnicity, socioeconomic status and education level (11). Focusing on Italy, the
seroprevalence of HCMV appear to be as high as 70–80% (12, 13).

Cytomegalovirus infection can occur during pregnancy and alongside the entire lifetime after delivery, by several transmission routes. As congenital HCMV infection (cHCMV), maternal primary and non-primary infection (exogenous reinfection with a different strain or endogenous viral reactivation) of virus during pregnancy can result in in utero transmission to the fetus (vertical route). Approximately 11% of live-born infants with cHCMV show abnormal clinical signs at birth: hematological disorders, cerebral malformation, chorioretinitis and sensorineural hearing loss (SNHL), the most common sequela (14, 15). Infants without symptoms at birth are also reported to be at risk of developing long-term hearing loss (16).

In the postnatal period, primary HCMV infections are acquired via several ways through contact with infected fluids (e.g., saliva, breast milk, blood products), at home and in nursery schools as community exposure (17). Breastfeeding is known to be the first close contact with the greatest impact, probably due to viral reactivation

in the mammary glands and subsequent excretion of Cytomegalovirus into the milk without clinical or
laboratory signs of systemic infection (negative serum IgM, negative viraemia) (18). During childhood and
early adulthood, HCMV is transmitted through exposure to saliva, stool and urine (10).

Among adults genital secretions are a common fluid for CMV shedding, consistent with several studies that identified sexual risk factors for CMV seropositivity or seroconversion (10, 13, 19). Another important transmission route for primary infection consists in solid organ transplantation (SOT), especially in cases where there is a serological mismatch between donor and recipient (the recipient is CMV seronegative and the donor is seropositive) (20). Otherwise, infection can occur as reactivation in those patients with risk factors such as intense immunosuppression, use of lymphocyte-depleting antibodies or prednisolone, acute rejection, older age in the donor and/or recipient, concomitant viral infections or genetic polymorphisms (21, 22).

HCMV infection is usually asymptomatic in immunocompetent people, although clinical symptoms of 95 primary infection may include a nonspecific glandular fever (mononucleosis) syndrome characterized by flu-96 like symptoms (23). Instead, in immunocompromised or transplanted patients, HCMV primary infection or 97 reactivation represent a fearsome complication resulting in a viral syndrome, characterized by fever and 98 malaise as well as leukopenia, thrombocytopenia and elevated liver enzymes. Pneumonia, hepatitis, 99 meningoencephalitis, pancreatitis or myocarditis may rarely be present, requiring admission to an intensive 100 care unit (20, 24). HCMV infection may also have indirect effects on graft dysfunction, acceleration of 101 coronary artery atherosclerosis, renal artery stenosis and the emergence of other opportunistic infections (25, 102 26). 103

Alongside serological tests and pp65 antigenemia, direct detection of HCMV DNA in clinical specimens is 104 currently the standard method for the diagnosis of HCMV infection (2, 27). Particularly, Quantitative 105 106 Polymerase chain reaction (qPCR) represents the gold standard and several IVD kits based on HCMV conserved regions were developed in order to detect and quantify HCMV DNA (28-32). Whole blood and 107 plasma are the most common specimens for HCMV qPCR (33-35), although cerebrospinal fluid (CSF) and 108 bronchoalveolar lavage fluid (BAL) are sometimes used (36). Scheduled monitoring of HCMV viremia in 109 immunocompromised individuals is critical for identifying patients at risk for CMV disease, evaluating 110 preemptive therapy and determining treatment response (2). 111

In addition to qPCR, other molecular techniques such as TMA (Transcription Mediated Amplification) have recently been developed and approved as commercial IVD kits. However, their clinical performance, especially on whole blood, is still under study.

Starting from this perspective, the main aim of our work was to evaluate the clinical performances of TMA chemistry on whole blood samples in a cohort of adult and pediatric individuals. Furthermore, focusing on transplanted patients, HCMV viremia was monitored over time with both chemistries. Finally, for an in-depth evaluation of whole blood matrix, a preliminary analysis was also performed on DBS samples in order to define the analytical performance of the TMA method starting from a minimum sample volume.

120 Materials and methods.

121 Setting and study design. The University Hospital "Città della Salute e della Scienza di Torino" (Turin, Italy)

is a regional tertiary hospital with 1900 beds spread over three structures: a general hospital, a pediatric clinicand a rehabilitation centre. The main area of excellence is represented by the transplantation of solid organs

124 (mainly kidney and liver) and tissues (corneas, skin, skeletal muscle) in adult and pediatric patients.

The study was performed on a total of 755 whole blood samples collected in the period May-November 2022 at Microbiology and Virology Laboratory of A.O.U. "Città della Salute e della Scienza di Torino" for the diagnosis of HCMV infection or the monitoring of viremia in immunocompromised/transplanted patients. All samples were collected in K2/EDTA Vacutainer[®] (Becton, Dickinson and Company, Franklin Lakes, USA).

129 Epidemiological details of patients and distribution of wards involved are resumed in Table 1.

- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137

140		Patients	A mean	ge median
141	Male	183	52	59
141	Female	140	48	54
142	Ward		Patients	Samples
	Kidney trans	splantation	65	106
143	HSC trans	splantation	27	107
1 4 4	Liver transplantation		13	37
144	Heart trans	splantation	10	20
145	Lung trans	splantation	4	22
4.45		Surgery	38	91
146	External facilities		38	63
147	Hae	ematology	26	44
147	N	ephrology	14	33
148		ICU/ED	11	32
140		Cardiology	9	18
149	Pn	neumology	7	17
		Oncology	7	1
150	-	my service	6	9
	Genera	l medicine	3	6
151	Gastroe	enterology	3	3
152	Paediatric	c oncology	13	58
192	Paediatric transplantat	tion centre	8	33
153	Paediatric n	ephrology	7	8
	Paediatric cardiology		4	14
154	General J	paediatrics	3	8
	Paediatric gastroe	enterology	2	11
155	Paediatric pr	eumology	1	1
	Paediatric ha	ematology	1	1
156	Rehabilitat	tion centre	3	12
157	Tendonnu	TOTAL	323	755

139 Table 1. Details of patients' epidemiology and wards involved.

158

qPCR chemistry. The laboratory routine method (Standard of Care), used as reference in the current study, was a dual-step process performed as follow: an initial extraction of HCMV DNA from whole blood samples with DSP Mini Kit on QIAsymphony SP/AS platform (Qiagen[®], Hilden, Germany) and subsequential amplification with CMV ELITE MGB[®] qPCR kit (ELITechGroup, Turin, Italy) on ABI 7500 Fast Dx instrument (Applied Biosystems, Waltham, USA). Finally, results were converted in International Unit on ml (IU/ml) with the software Real Time System Analysis Software V. 2.0 (release 1.9991) (ELITechGroup,

Turin, Italy). The tested viral region was the exon 4 region of the CMV MIEA gene (major immediate earlyantigen, HCMVUL123) with an amplicon size of 79 bp.

TMA chemistry. Whole blood samples were diluted in a prefilled secondary tube containing the Aptima[®] 167 Whole Blood Diluent (Hologic Inc., Marlborough, USA) to a volume of 500 µl and 1425 µl, respectively. 168 Then, each sample was loaded onto Panther system automated platform (Hologic Inc., Marlborough, USA) 169 and tested with the Aptima CMV Quant assay kit (Hologic Inc., Marlborough, USA). The assay has three 170 main steps: target capture, target amplification using TMA and detection of amplification products. Finally, 171 the results were converted from copies/mL to IU/mL using a conversion factor equation embedded in the 172 Panther software. For this kit, the viral region tested was the UL56 gene in the unique long (UL) region of the 173 CMV genome with an amplicon size of 108 bp. 174

Both chemistries (qPCR and TMA) have been standardized to the WHO 1st International Standard for human
cytomegalovirus (NIBSC code: 09/162, United Kingdom).

DBS. In order to evaluate the clinical performance of TMA chemistry on Dried Blood Spot (DBS), 52 whole 177 blood positive samples with quantifiable viremia were selected and processed according to the following 178 protocol: 50 µl of blood sample (approximately the volume of a drop) were spotted on Whatman protein 179 saverTM 903TM cards (GE HealthCare, Marlborough, USA), dried for at least 24 hours at room temperature 180 and stored at the same temperature for one week. Subsequently, each sample was pretreated with Aptima[™] 181 DBS Extraction Buffer (Hologic Inc., Marlborough, USA) according to the manufacturer's instructions: 182 briefly, 12 mm³ of DBS specimen was added to 1 ml of DBS Extraction Buffer and gently stirred at room 183 temperature for 30 minutes. Then, vials containing the extracted DBS were centrifuged for 2 minutes at 3,000 184 g and loaded onto the Panther System. Each sample was tested in duplicate with Aptima CMV Quant assay 185 kit. 186

187 Clinical agreement. Whole blood samples were tested simultaneously with qPCR and TMA chemistries in 188 order to evaluate overall sensitivity, specificity and quantification agreement. Moreover, 12 selected patients 189 were monitored in terms of HCMV viraemia for up to three months of hospitalization; the inclusion criteria


- 190 for patients' selection were: (1) solid organ transplantation, (2) no less than four quantifications for at least 14
- days, (3) HCMV viraemia detectable in the first blood sampling with at least one of the two tested methods.
- 192 Statistical analysis. Data were analyzed as Log₁₀-transformed values. In the correlation analysis, only
- samples in which the assays had quantitative values were considered. The correlation between the quantitative
- 194 results was evaluated with linear regression analysis and Bland-Altman plot. The correlation coefficient was
- 195 calculated using Pearson's correlation. All analysis was performed using MedCalc statistical software
- 196 Program version 20.305 (MedCalc Software Ltd, Ostend, Belgium).
- **Results.** TMA and qPCR performance data showed 99.28% agreement for quantified detected samples and
 89.39% agreement for those negative between the two tested methods (Table 2). Cohen's kappa coefficient
 was excellent (K-value: 0.87).
- 200 Table 2. Comparison of clinical agreement between TMA and qPCR assays.

201	TMA			Total	Agreement	
	qPCR	Not detected	Detected	Quantified	Total	້ (%)
202	Not detected	337	34	6	377	89.39%
03	Detected	9	23	71	103	22.33%
05	Quantified	0	2	273	275	99.27%
04	Total	346	59	350	755	

Compared to conventional qPCR, the TMA assay resulted in a higher number of detected or quantified
samples (10.61%): 5 samples quantified with TMA chemistry had a mean value between 2.27 and 2.84 Log₁₀
IU/ml, while one samples had a higher value of 3.92 Log₁₀ IU/ml. When repeated, the result was confirmed.
Additionally, for samples quantified with TMA assay and detected by qPCR, values ranged between 2.0 and
Log₁₀ IU/ml, with the highest distribution for those 2.4 - 2.8 Log₁₀ IU/ml (36/71, 50.70%) (Figure 1).

- 210
- 211
- 212
- 213
- 214
- 215

Figure 1. Distribution of Log₁₀ IU/ml values with TMA assay in qPCR detected samples.



225

217

218

219

220

221

222

223


224

Otherwise, 9 samples tested positive with qPCR and not detected with TMA, while two were quantified by qPCR assay only: the mean value was $2.65 \pm 0.14 \text{ Log}_{10} \text{ IU/ml}$ (Table 1).

A total of 273 samples had quantifiable results on both assays and were used for the correlation analysis.

Deming's regression analysis showed a significant correlation between the two chemistries: the linear regression line was calculated as follows, Y = 0.4581 + 0.8024 x with an $R^2 = 0.7142$ (Figure 2). Pearson's correlation coefficient value was 0.8796 (95% CI: 0.8496 to 0.9039) (P-value < 0.0001).

Figure 2. Log₁₀-transformed quantitative viral load agreement for TMA and qPCR chemistry: linear




243

The mean viral load (±SD) of the TMA assay was $3.79 \pm 0.83 \text{ Log}_{10}$ IU/ml, while that obtained by qPCR was 3.50 ± 0.80 Log_{10} IU/ml. The Bland-Altman analysis (Figure 3) yielded a mean bias of -0.29 Log_{10} IU/ml (SD ± 0.40 Log_{10} IU/ml). The lower and upper limits of agreement were -1.07 (95% CI: -1.15 to -0.99) and 0.50 (95% CI: 0.42 to 0.58), respectively.

248

Figure 3. Log₁₀-transformed quantitative viral load agreement for TMA and qPCR chemistry: Bland-


251 Altman plot.



According to the abovementioned criteria, 12 transplanted patients were monitored for a period ranging from 262 17 days to 100 days, depending on the hospital stay (Figure 4). All patients tested positive for both methods 263 at time 0, except one (Figure 4, Patient #7) in which initial viremia was only detectable by TMA assay. Overall, 264 in the samples tested from these patients, the mean difference between qPCR and TMA chemistries was -265 0.59 ± 0.63 Log₁₀ IU/ml. The strictest agreement resulted for patient number 5, 9, 10, 12 (mean difference – 266 0.23 ± 0.06 Log₁₀ IU/ml). Interestingly, the patient #1 resulted steadily positive for up to three months of 267 monitoring with TMA assay, while qPCR tested negative at day 17. However, the previously day, both assays 268 resulted positive (2.48 or less and 3.45 Log₁₀ IU/ml respectively for qPCR and TMA chemistry). When 269 retested, the trend of HCMV viremia was confirmed in the samples from both days. 270

The most evident difference between tested assay resulted in patient #2 with a mean value of -1.12 ± 0.84 Log₁₀ IU/ml.

Figure 4. Trend of HCMV viremia with qPCR and TMA assays in transplanted patients.



52 quantified samples tested simultaneously as whole blood and spotted on DBS. Overall agreement was 86.54% (Table 3). 7 specimens (13.46%) resulted negative and, using a conversion factor of 36.4 (37), the mean value was $1.72 \pm 0.54 \text{ Log}_{10}$ IU/ml. Among positive results, 8 samples (15.38%) tested detected but not quantified on DBS: tough the conversion factor abovementioned, mean value for those specimens was $1.43 \pm$ 0.42 Log₁₀ IU/ml.


280	Table 3. TMA assay:	overall agreement betwee	en whole blood samples ar	d spotted on DBS.

		-	
281		Number of samples	(%)
282	Not detected	7	13.46%
202	Detected	8	15.38%
283	Quantified	37	71.15%
284	Total	52	
204	Overall	agreement	86.54%
285			

- Focusing on 37 quantified specimens both on whole blood and DBS, regression analysis using the aforesaid
- 287 conversion factor showed a significant correlation between the two chemistries: the linear regression line was
- calculated as follows, Y = 1.4257 + 0.5936 x with an $R^2 = 0.7232$ (Figure 5). Pearson's correlation coefficient
- value was 0.8977 (95% CI: 0.8090 to 0.9464) (P-value < 0.0001).

Figure 5. Log₁₀-transformed quantitative viral load agreement for whole blood samples and the same

291 spotted as DBS* with TMA assay: linear regression.



*For DBS samples, conversion to result on whole blood, the following formula was applied: Log₁₀(IU/ml*36.4)

307

Discussion. Early detection of HCMV viraemia is pivotal to identify progressing infection and patients at high risk, which required antiviral therapy. Especially, the effectiveness of a pre-emptive therapy relies on accurate laboratory tests to monitor HCMV infection (38). Specimens currently recommended as the gold standard for monitoring the presence of HCMV DNA are whole blood and plasma that contain it respectively in monocytes and as free fragmented HCMV genome, which is released from infected cells (34). Although there is no

consensus on the optimal blood compartment for routine molecular testing of HCMV DNA and the stability 313 of the viral genome in both whole blood and plasma up to 14 at 4°C (39, 40), the higher sensitivity of whole 314 blood and its higher HCMV DNA vield make it an optimal sample for monitoring viral load in 315 immunocompromised patients (41). Moreover, in order to enhance interlaboratory agreement of HCMV DNA 316 quantification, also in relation to the first WHO International Standard established in October 2010, different 317 diagnostic workflows (extraction and amplification) were evaluated to define an appropriate conversion factor 318 (CF) from genome/ml to IU/ml both on whole blood and plasma in a multicentric study (42, 43). Also due to 319 this standardization, it has been possible to better understand viral kinetics and threshold values for predicting 320 HCMV disease: although the viral load peak was reached simultaneously in the two blood compartments, 321 HCMV viraemia in whole blood was constantly higher (about 1 log₁₀ IU/ml) than in plasma since the onset 322 of infection until the peak of viral load and it decreased more rapidly than in plasma, thus avoiding unnecessary 323 prolonged treatment and saving in terms of drug toxicity and cost (44). 324

At the time of writing, several qPCR diagnostics assays have been developed and are currently available for identification and quantification of HCMV in plasma and whole blood; besides these, also a recently new TMA assay was introduced.

Differently from qPCR, target amplification via TMA is a transcription-mediated nucleic acid amplification method that uses two enzymes, Moloney murine leukemia virus (MMLV) reverse transcriptase and T7 RNA polymerase. The first enzyme generates a DNA copy of UL56 HCMV gene containing a promoter sequence for T7 RNA polymerase, which subsequently produces multiple copies of RNA amplicon from the viral DNA copy template. Detection is achieved using single-stranded nucleic acid torches, provide of a fluorophore and a quencher, that hybridize specifically to the amplicon of HCMV DNA.

Although correlation between qPCR and TMA chemistries for HCMV detection was assessed on plasma and other types of samples with excellent concordance (45, 46), EDTA/whole blood as clinical samples were not yet investigated.

In this study, we evaluated the performance of the TMA assay (Aptima[®] CMV Quant Assay) and compared the data with our qPCR SoC (CMV ELITe MGB[®] Kit). Clinical agreement between two chemistries was excellent (99.28% and 89.39% for quantified and negative samples, respectively). Moreover, TMA assay

quantify at an average of 0.29 Log_{10} IU/mL higher compared to the qPCR assay, as showed in the Bland-Altman plot (Figure 3). Since mean difference was less than 0.5 Log, the cut-off to consider load changes biologically important (47), our results could suggest no clinical implication if diagnostic platform will be changed. However, this could be applied for our clinical setting where a side-to-side evaluation has been performed. Indeed, data about plasma samples showed a mean difference variable between – 0.20 and 0.58 Log_{10} IU/mL, according to TMA compared with different aPCR platform (45, 46).

Herein, TMA assay resulted more sensitive, resulting in a higher number of samples with a defined viral load 346 (Table 2). This is probably due to the differences between the two methods in terms of Limit of Detection 347 (LoD) and Limit of Quantification (LoQ). This latter amounted on 2.18 Log₁₀ IU/ml for TMA assay and 2.48 348 Log₁₀ IU/ml for qPCR; several discrepant samples stood between the range 2.2 - 2.8 Log₁₀ IU/ml, thus near 349 the lower LoQ of the qPCR assay (Figure 1). It is noteworthy that TMA assay needed a higher extraction 350 volume (700 µl) but it must be diluted in ratio 1:2.85 with the appropriate preparation buffer, while for qPCR 351 Starting volume is 200 µl of whole blood directly from vacutainer eluted in a final volume of 110 µl. Moreover, 352 TMA assay was evaluated with a fully automated sample-to-result platform, while two different platforms, 353 one for HCMV DNA extraction and the other for amplification, were used in combination for qPCR SoC. 354

All abovementioned aspects, together with gene target and amplicon size (48), have to be taken into account to explain the differences between the two tested methods.

TMA chemistry performances were assessed to monitor viremia in transplanted patients; twelve individuals 357 were selected and tested for a period of time with both assays. Our data showed a good overlay until more 358 than three months, with TMA values on average higher than qPCR (Figure 4), in agreement with overall 359 360 results. The major discrepancy was observed in patient 1, in which qPCR resulted suddenly not detected while TMA assay showed a linear trend in HCMV viraemia. Nevertheless, due to the reduced number of patients 361 enrolled, no correlation with antiviral therapy and clinical outcome were evaluated. Another limitation of our 362 study in this patients' cohorts is the lackness of data about antiviral-resistant HCMV strains that could affect 363 the compared methods. 364

For an in-depth analysis of whole blood as clinical specimen, TMA clinical performances were tested also with low volumes such as those obtained onto DBS. In this preliminary study, 52 positive whole blood samples

were spotted onto DBS and results showed 86.54% of agreement (Table 3). For quantified specimens, applying 367 the abovementioned conversion factor of 36.4, linear regression was excellent (Figure 5). Focusing on 368 negative and detected DBS samples, mean viral load expected to be on whole blood was respectively $1.72 \pm$ 369 $0.54 \text{ Log}_{10} \text{ IU/ml}$ and $1.43 \pm 0.42 \text{ Log}_{10} \text{ IU/ml}$, thus under the LoD of TMA assay (2.18 Log_{10} IU/ml). Since 370 low viral loads are unlikely to be associated to clinical consequences in cCMV infection (49), results herein 371 reported can be considered acceptable for clinical use. To our knowledge, this is the first evaluation of TMA 372 on low volumes resulted on Dried Blood Spot. However, the most important limit of this preliminary analysis 373 is the need for a higher number of tested specimens obtained directly from patients, even for calculate a most 374 suitable conversion factor between whole blood and DBS. 375

The excellent TMA testing results obtained in the present study, together with those of other studies, allow the opportunity of further studies to better understand the impact of TMA assay, especially in transplanted patients, on clinical management and decision to begin preemptive therapy or antiviral prophylaxis. However, due to its recent introduction for HCMV diagnosis, no data of comparison between plasma and whole blood are available to assess the most suitable matrix with TMA chemistry.

Alongside clinical and analytical performances, TMA assay showed the advantage to be carried out onto a fully automated system with random and continuous access, thus eliminating the need to batch samples and leading to faster turnaround time.

Laboratories evaluating a change to a different diagnostic system must considered all previously mentioned aspects performing a side-to-side testing using both current and new assays to understand the most suitable diagnostic workflow and clinical matrix.

TMA chemistry is a reliable diagnostic assay that allows accurate assessment of HCMV viremia on whole blood specimens, even with small volumes such as those of Guthrie card collected for diagnosis of cCMV infection. Moreover, this is the first TMA kit with FDA and CE-IVD approval on whole blood samples, thus clinical laboratories can easily incorporate this test in their routine molecular workflows. The availability of an automated platform with minimal hand-on time also enables timely diagnosis, prognosis and monitoring of HCMV infected patients.

- 394 Acknowledgment. This research was supported by EU funding within the MUR PNRR Extended Partnership
- initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT).
- 396
- 397

398 **References.**

- Griffiths P, Reeves M. 2021. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol 2021 1912 19:759–773.
- 401 2. A. Ross S, Novak Z, Pati S, B. Boppana S. 2011. Diagnosis of Cytomegalovirus Infections. Infect
 402 Disord Drug Targets 11:466.
- Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, Thomson M, Griffiths PD,
 Wilkinson GWG, Schulz TF, Davison AJ. 2010. Sequences of complete human cytomegalovirus
 genomes from infected cell cultures and clinical specimens. J Gen Virol 91:605.
- 4. Bhella D, Rixon FJ, Dargan DJ. 2000. Cryomicroscopy of human cytomegalovirus virions reveals
 more densely packed genomic DNA than in herpes simplex virus type 1. J Mol Biol 295:155–161.
- Yu X, Jih J, Jiang J, Hong Zhou Z. 2017. Atomic structure of the human cytomegalovirus capsid with
 its securing tegument layer of pp150 HHS Public Access. Science (80-) 356.
- 6. Tomtishen J. 2012. Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virol J
 9:1–9.
- 412 7. Kalejta RF. 2008. Tegument Proteins of Human Cytomegalovirus. Microbiol Mol Biol Rev 72:249–
 413 265.
- 414 8. Garoff H, Hewson R, Opstelten D-JE. 1998. Virus Maturation by Budding. Microbiol Mol Biol Rev
 415 62:1171.
- 416 9. Homman-Loudiyi M, Hultenby K, Britt W, Söderberg-Nauclér C. 2003. Envelopment of Human
 417 Cytomegalovirus Occurs by Budding into Golgi-Derived Vacuole Compartments Positive for gB, Rab
 418 3, Trans-Golgi Network 46, and Mannosidase II. J Virol 77:3191–3203.
- Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202–213.
- Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, Schmidt E, Natenshon
 A, Talarico C, Buck PO, Diaz-Decaro J. 2022. A systematic literature review of the global
 seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine
 development. BMC Public Health 22:1–15.
- Barbi M, Binda S, Caroppo S, Calvario A, Germinario C, Bozzi A, Tanzi ML, Veronesi L, Mura I,
 Piana A, Solinas G, Pugni L, Bevílaqua G, Mosca F. 2006. Multicity Italian study of congenital
 cytomegalovirus infection. Pediatr Infect Dis J 25:156–159.
- Rubinacci V, Fumagalli M, Meraviglia G, Gianolio L, Sala A, Stracuzzi M, Dighera A, Zuccotti GV,
 Giacomet V. 2022. Congenital CMV, Lights and Shadows on Its Management: The Experience of a
 Reference Center in Northern Italy. Child 2022, Vol 9, Page 655 9:655.
- 431 14. Lazzarotto T, Blázquez-Gamero D, Delforge ML, Foulon I, Luck S, Modrow S, Leruez-Ville M.
 432 2020. Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and
 433 Management From a Panel of European Experts. Front Pediatr 8:13.
- 434 15. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital

- 435 cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276.
- Bartlett AW, McMullan B, Rawlinson WD, Palasanthiran P. 2017. Hearing and neurodevelopmental
 outcomes for children with asymptomatic congenital cytomegalovirus infection: A systematic review.
 Rev Med Virol 27.
- 439 17. Gökçe Ş. 2019. Human Cytomegalovirus Infection: Biological Features, Transmission, Symptoms,
 440 Diagnosis, and Treatment, p. . *In* Thomasini, RL (ed.), Human Herpesvirus Infection. IntechOpen,
 441 Rijeka.
- 18. Chiavarini M, Bragetti P, Sensini A, Cenci E, Castronari R, Rossi MJ, Fantauzzi A, Minelli L. 2011.
 Breastfeeding and transmission of cytomegalovirus to preterm infants. Case report and kinetic of
 CMV-DNA in breast milk. Ital J Pediatr 37:6.
- Hyde TB, Schmid DS, Cannon MJ. 2010. Cytomegalovirus seroconversion rates and risk factors:
 implications for congenital CMV. Rev Med Virol 20:311–326.
- Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TMV, Campos SV, Ramos JF, Latif AZA,
 Litvinov N, Maluf NZ, Filho HHC, Pannuti CS, Lopes MH, dos Santos VA, Linardi C da CG,
 Yasuda MAS, Marques HH de S. 2015. Cytomegalovirus infection in transplant recipients. Clinics
 70:515.
- Shimada T, Higashida-Konishi M, Izumi K, Hama S, Oshige T, Oshima H, Okano Y. 2022. Risk
 factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy
 for rheumatic diseases: a retrospective study. Sci Reports 2022 121 12:1–8.
- 454 22. Humar A, Snydman D. 2009. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9
 455 Suppl 4.
- Van Zuylen WJ, Hamilton ST, Naing Z, Hall B, Shand A, Rawlinson WD. Congenital
 cytomegalovirus infection: Clinical presentation, epidemiology, diagnosis and prevention
 https://doi.org/10.1177/1753495X14552719.
- 459 24. Requião-Moura LR, deMatos AC ristin. C, Pacheco-Silva A. 2015. Cytomegalovirus infection in
 460 renal transplantation: clinical aspects, management and the perspectives. einstein (São Paulo) 13:142–
 461 148.
- 462 25. Paya C V. 1999. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis an
 463 Off J Transplant Soc 1 Suppl 1:8–12.
- 26. Diena D, Allesina A, Fop F, Mella A, Cavallo R, Costa C, Dolla C, Gallo E, Rosa FG De, Lavacca A,
 Giraudi R, Mariano F, Biancone L. 2023. Relationship between Cytomegalovirus Viremia and LongTerm Outcomes in Kidney Transplant Recipients with Different Donor Ages. Microorganisms
 11:458.
- 468 27. Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L, Simonazzi G, Pellett
 469 PE, Schmid DS. 2020. Clinical Diagnostic Testing for Human Cytomegalovirus Infections. J Infect
 470 Dis 221:S74.
- 471 28. Gu J, Ji H, Liu T, Chen C, Zhao S, Cao Y, Wang N, Xiao M, Chen L, Cai H. 2022. Detection of
 472 cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV
 473 gastroenteritis. Virol J 19:1–10.
- 474 29. Novak Z, Chowdhury N, Ross SA, Pati SK, Fowler K, Boppana SB. 2011. Diagnostic consequences of cytomegalovirus glycoprotein B polymorphisms. J Clin Microbiol 49:3033–3035.
- 30. Rasmussen L, Geissler A, Cowan C, Chase A, Winters M. 2002. The genes encoding the gCIII
 complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol
 76:10841–10848.

479 480	31.	Leruez-Ville M, Ducroux A, Rouzioux C. 2008. Exon 4 of the human cytomegalovirus (CMV) major immediate-early gene as a target for CMV real-time PCR. J Clin Microbiol 46:1571–1572.
481 482	32.	Chou S, Dennison KM. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 163:1229–1234.
483 484 485 486 487	33.	Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F. 2018. Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant 24:1699–1706.
488 489 490	34.	Rzepka M, Depka D, Gospodarek-Komkowska E, Bogiel T. 2022. Whole Blood versus Plasma Samples-How Does the Type of Specimen Collected for Testing Affect the Monitoring of Cytomegalovirus Viremia? Pathog (Basel, Switzerland) 11.
491 492	35.	Rzepka M, Depka D, Gospodarek-Komkowska E, Bogiel T. 2023. Diagnostic Value of Whole-Blood and Plasma Samples in Epstein-Barr Virus Infections. Diagnostics (Basel, Switzerland) 13.
493 494 495	36.	Beam E, Germer JJ, Lahr B, Yao JDC, Limper AH, Binnicker MJ, Razonable RR. 2018. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia. Clin Transplant 32:e13149.
496 497 498 499	37.	Yek C, Massanella M, Peling T, Lednovich K, Nair S V., Worlock A, Vargas M, Gianella S, Ellis RJ, Strain MC, Busch MP, Nugent CT, Richman DD. 2017. Evaluation of the aptima HIV-1 Quant Dx assay for HIV-1 RNA quantitation in different biological specimen types. J Clin Microbiol 55:2544–2553.
500 501 502	38.	Ghisetti V, Barbui A, Franchello A, Varetto S, Pittaluga F, Bobbio M, Salizzoni M, Marchiaro G. 2004. Quantitation of Cytomegalovirus DNA by the Polymerase Chain Reaction as a Predictor of Disease in Solid Organ Transplantation. J Med Virol 73:223–229.
503 504	39.	Abdul-Ali D, Kraft CS, Ingersoll J, Frempong M, Caliendo AM. 2011. Cytomegalovirus DNA stability in EDTA Anti-Coagulated Whole Blood and Plasma Samples. J Clin Virol 52:222.
505 506	40.	Koidl C, Bozic M, Marth E, Kessler HH. 2008. Detection of CMV DNA: Is EDTA whole blood superior to EDTA plasma? J Virol Methods 154:210–212.
507 508 509	41.	Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya C V. 2002. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73:968–973.
510 511 512 513 514	42.	Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, Paba P, Perno CF, Gaeta A, Antonelli G, Sodano G, Santangelo R, Sanguinetti M, Vatteroni ML, Barzon L, Palù G, Abbate I, Capobianchi MR, Piccirilli G, Lazzarotto T, Baldanti F, Cavallo R. 2019. Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Diagn Microbiol Infect Dis 95:152–158.
515 516 517	43.	Fryer JF, Heath AB, Minor PD, Group CS. 2016. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology https://doi.org/10.1016/j.biologicals.2016.04.005.
518 519 520 521 522	44.	Lazzarotto T, Chiereghin A, Piralla A, Gibertoni D, Piccirilli G, Turello G, Campanini G, Gabrielli L, Costa C, Comai G, La Manna G, Biancone L, Rampino T, Gregorini M, Sidoti F, Bianco G, Mauro MV, Greco F, Cavallo R, Baldanti F. 2020. Kinetics of cytomegalovirus and Epstein-Barr virus DNA in whole blood and plasma of kidney transplant recipients: Implications on management strategies. PLoS One 15:e0238062.
523	45.	Lima A, Healer V, Rowe L, Silbert S. 2023. Performance evaluation of the Aptima CMV quant assay

- using plasma and non-plasma samples. J Clin Virol 164:105467.
- 46. Sam SS, Rogers R, Ingersoll J, Kraft CS, Caliendo AM. 2023. Evaluation of Performance
 Characteristics of the Aptima CMV Quant Assay for the Detection and Quantitation of CMV DNA in
 Plasma Samples. J Clin Microbiol 61.
- 47. Kraft CS, Armstrong WS, Caliendo AM. 2012. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 54:1793–1797.
- 48. Cook L, Starr K, Boonyaratanakornkit J, Hayden R, Sam SS, Caliendo AM. 2018. Does size matter?
 Comparison of extraction yields for different-sized DNA fragments by seven different routine and
 four new circulating cell-free extraction methods. J Clin Microbiol 56.
- 49. Bottino P, Balloco C, Rittà M, Bianco G, Sidoti F, Cavallo R, Costa C. 2020. Evaluation of CMV
 DNA in dried blood spot 43:93–95.
- 535